Clearside Biomedical, Inc. - Common Stock (CLSD)

Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.

This week's M&A news includes strategic pivots and stumbles galore, with updates from WK Kellogg, Matador Restaurant and Windsurf.

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps.

Clearside Biomedical's CLS-AX Phase 2b trial for wet AMD met primary and secondary endpoints, showing stable vision and reduced injection frequency by 84% over 24 weeks, with no serious adverse events reported.

CLSD stock results show that Clearside Biomedical beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

Clearside Biomedical pioneers suprachoroidal drug delivery for precise, effective treatment of retinal diseases. Oppenheimer rates CLSD Outperform with a $5 target, citing its innovative SCS Microinjector and strategic partnerships.